Amgen’s KRAS Triumph, Eric Lander in the Saddle, and EQRx Takes Aim at PD-L1

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Biogen’s Alzheimer’s Controversy, Cytokine Startups Reload, and Vaccines Beat Variants
GSK, Vir Win Antibody OK, Sanofi-GSK Moves to Phase III, & a Day One IPO
GSK Persists with Vaccines, ASCO Abstracts, & Biogen Gene Therapy Fizzles
Pfizer Advances to Adolescents, Xontogeny’s New Fund & Rekindling Curiosity